Currently out of the existing stock ratings of Whitney Ijem, 81 are a BUY (77.88%), 17 are a HOLD (16.35%), 6 are a SELL (5.77%).

Whitney Ijem

Work Performance Price Targets & Ratings Chart

Analyst Whitney Ijem, currently employed at CANACCORD, carries an average stock price target met ratio of 31.36% that have a potential upside of 23.51% achieved within 225 days.

Whitney Ijem’s has documented 206 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VERV, Verve Therapeutics at 17-Jun-2025.

Wall Street Analyst Whitney Ijem

Analyst best performing recommendations are on KRYS (KRYSTAL BIOTECH).
The best stock recommendation documented was for KRYS (KRYSTAL BIOTECH) at 6/21/2019. The price target of $48 was fulfilled within 26 days with a profit of $18.85 (64.67%) receiving and performance score of 24.87.

Average potential price target upside

of $106.3 (59.42%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $57.42 (11.9%) on VRTX (VERTEX PHARMACEUTICALS).
of $28.13 (71.94%) on KRYS (KRYSTAL BIOTECH).

SRPT Sarepta Therapeutics GBIO Generation Bio Co PASG Passage Bio RCKT Rocket Pharmaceuticals RGLS Regulus Therapeutics TNYA Tenaya Therapeutics ALNY Alnylam Pharmaceuticals BMRN Biomarin Pharmaceutical GILD Gilead Sciences KRYS Krystal Biotech RYTM Rhythm Pharmaceuticals SGMO Sangamo Therapeutics TSHA Taysha Gene Therapies VRTX Vertex Pharmaceuticals ARCT Arcturus Therapeutics Holdings NTLA Intellia Therapeutics SGTX Sigilon Therapeutics VERV Verve Therapeutics RARE Ultragenyx

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Uy Ear (MIZUHO)